HERCULES, Calif., July 07, 2025--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), announced the launch of four new Droplet Digital™ PCR (ddPCR™) platforms. The newly introduced instruments include Bio-Rad’s QX Continuum™ ddPCR ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), provides an overview of advances supporting the Company’s overall corporate strategy to improve science and healthcare in the year to date. Centered ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Bio-Rad Laboratories, Inc. stands tenth on our list and is currently making waves for launching a new ...

Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...

Bio-Rad will be launching two new real-time PCR detection tools to be used for in-vitro diagnostic testing. Bio-Rad Laboratories, a life science research and clinical diagnostics product provider, ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the CFX Opus Deepwell Dx Real-Time PCR System, ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that the company’s ...

The SARS-CoV-2 Droplet Digital PCR (ddPCR) test runs on Bio-Rad's QX200 and QXDx ddPCR systems. The high sensitivity of the test makes it well suited to screening upper respiratory samples in patients ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its SARS-CoV-2 ...